Cargando…
Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa?
Mycoplasma pneumonia e is a bacterium that lacks a cell wall. It produces infections all It produces infections worldwide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The trea...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238793/ https://www.ncbi.nlm.nih.gov/pubmed/36966384 http://dx.doi.org/10.37201/req/118.2022 |
_version_ | 1785053356684738560 |
---|---|
author | Varela, Ana Isabel Álvaro Pérez, Aitziber Aguinaga Ortega, Ana Navascués Catalán, Jesús Castilla Baquedano, Carmen Ezpeleta |
author_facet | Varela, Ana Isabel Álvaro Pérez, Aitziber Aguinaga Ortega, Ana Navascués Catalán, Jesús Castilla Baquedano, Carmen Ezpeleta |
author_sort | Varela, Ana Isabel Álvaro |
collection | PubMed |
description | Mycoplasma pneumonia e is a bacterium that lacks a cell wall. It produces infections all It produces infections worldwide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique. |
format | Online Article Text |
id | pubmed-10238793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Sociedad Española de Quimioterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-102387932023-06-04 Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? Varela, Ana Isabel Álvaro Pérez, Aitziber Aguinaga Ortega, Ana Navascués Catalán, Jesús Castilla Baquedano, Carmen Ezpeleta Rev Esp Quimioter Revisión Mycoplasma pneumonia e is a bacterium that lacks a cell wall. It produces infections all It produces infections worldwide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique. Sociedad Española de Quimioterapia 2023-03-27 2023 /pmc/articles/PMC10238793/ /pubmed/36966384 http://dx.doi.org/10.37201/req/118.2022 Text en © The Author 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Revisión Varela, Ana Isabel Álvaro Pérez, Aitziber Aguinaga Ortega, Ana Navascués Catalán, Jesús Castilla Baquedano, Carmen Ezpeleta Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? |
title | Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? |
title_full | Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? |
title_fullStr | Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? |
title_full_unstemmed | Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? |
title_short | Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? |
title_sort | mycoplasma pneumoniae y resistencias a macrólidos: ¿conocemos la situación en europa? |
topic | Revisión |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238793/ https://www.ncbi.nlm.nih.gov/pubmed/36966384 http://dx.doi.org/10.37201/req/118.2022 |
work_keys_str_mv | AT varelaanaisabelalvaro mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa AT perezaitziberaguinaga mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa AT ortegaananavascues mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa AT catalanjesuscastilla mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa AT baquedanocarmenezpeleta mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa |